June 2020 FDA Recall Metformin Hydrochloride by Lupin Pharmaceuticals Inc.
D-1334-2020 - CGMP Deviations

This Class II drug recall was voluntarily initiated by Lupin Pharmaceuticals Inc. on June 11, 2020 for the product Metformin Hydrochloride. The FDA reported the reason for recall as cgmp deviations. The product was distributed in Product was distributed throughout the United States. and the recall is currently terminated.

Recall Number: D-1334-2020

Reason for Recall
CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level
Initiated
06-11-2020
Reported
07-01-2020
Quantity
6,540 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Lupin Pharmaceuticals Inc.
Product was distributed throughout the United States.
Metformin Hydrochloride Extended-release Tablets USP, 500 mg, 60 count bottle, Rx only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD Manufactured by: Lupin Limited Goa INDIA (NDC 68180-336-07)

Batch or Lot Expiration Information

Batch# G901203, exp. date 12/2020